

Notice Regarding Receipt of Dividends from Consolidated Subsidiary

Tokyo, Japan and Cambridge, UK, 8 December 2025 – Nxera Pharma Co. Ltd (“Nxera” or “the Company; TSE 4565) announces that it has received dividends from Nxera Pharma UK Limited, its consolidated subsidiary. This matter falls under the requirements for submission of extraordinary report pursuant to the provisions of Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Act and Article 19, Paragraph 2, Item 12 of the Cabinet Office Ordinance on Disclosure of Corporate Affairs.

1. Summary of dividends

- (1) Total amount of dividends: JPY 8,193 million
- (1) Dividend income: JPY 2,793 million
- (2) Date of receipt: 26 November 2025
- (3) Name of subsidiary: Nxera Pharma UK Limited

2. Impact on consolidated financial results

According to this matter, the dividend income of JPY 2,793 million will be recorded as non-operating income in the Company’s non-consolidated financial statements for the fiscal year ending 31 December 2025. Since the dividends are from its consolidated subsidiary, there is no impact on the Company’s consolidated financial results.

–END–

About Nxera Pharma

Nxera Pharma is a technology powered biopharma company in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally.

We have built an agile, new-generation commercial business in Japan to develop and commercialize innovative medicines, including several launched products, to address this high value, large and growing market and those in the broader APAC region.

Behind that, and powered by our unique NxWave™ discovery platform, we are advancing an extensive pipeline of over 30 active programs from discovery through to late clinical stage internally and in partnership with leading pharma and biotech companies. This pipeline of potentially first- and best-in-class candidates is focused on addressing major unmet needs in some of the fastest-growing areas of medicine across obesity and metabolic disorders, neurology/neuropsychiatry and immunology and inflammation.

Nxera employs approximately 400 talented people at key locations in Tokyo and Osaka (Japan), London and Cambridge (UK), Basel (Switzerland) and Seoul (South Korea) and is listed on the Tokyo Stock Exchange (ticker: 4565).

For more information, please visit www.nxera.life

LinkedIn: [@NxeraPharma](#) | X: [@NxeraPharma](#) | YouTube: [@NxeraPharma](#)

Enquiries:

Media and Investor Relations

Shinya Tsuzuki, VP, Head of Investor Relations

Shinichiro Nishishita, VP Investor Relations, Head of Regulatory Disclosures

Maya Bennison, Communications Manager

+81 (0)3 5962 5718 | +44 (0)1223 949390 IR@Nxera.life

MEDiSTRAVA (for International Media)

Mark Swallow, Frazer Hall, Erica Hollingsworth

+44 (0)203 928 6900 | Nxera@medistrava.com

Forward-looking statements

This press release contains forward-looking statements, including statements about the discovery, development, and commercialization of products. Various risks may cause Nxera Pharma Group's actual results to differ materially from those expressed or implied by the forward looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.